Concretely: a 27G needle · 3.33 mg/mL.
Please show the division. I want to check my own against yours.
I would like the general form as well as the specific number, so I can apply it again.
Is my approach right even if my number is wrong?
The single most important fact about dead space is that it is almost entirely in the hub cone, not in the needle, which is why changing needle gauge or length barely changes your losses.
The needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.
| Vial | Diluent | Concentration | 0.25 mg | 0.5 mg | 1 mg | 2.5 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 5 mg | 2 mL | 2.5 mg/mL | 10 u | 20 u | 40 u | 100 u |
| 10 mg | 1 mL | 10 mg/mL | 2.5 u | 5 u | 10 u | 25 u |
| 10 mg | 2 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 10 mg | 3 mL | 3.33 mg/mL | 7.5 u | 15 u | 30 u | 75 u |
Units are U-100 insulin units, where 1 unit = 0.01 mL. Divide dose by concentration for millilitres, then multiply by 100.
Corollary that follows immediately: changing needle gauge or length barely changes your losses.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
The switch nearly doubles your vial, which is better than most other optimisations combined.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe underlying point is that at 100 µL draws the dead-space penalty with a luer-lock is 84 per cent per draw — the cost is genuinely catastrophic.
At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.
Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.
Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.
If cost matters, this is the first thing to change, not the last.
On the detail: this is arithmetic, so let us do the arithmetic and see where the losses actually are.
Be sceptical of anything advertised as low dead space that retains a conventional plunger tip: if you can look into the fitting with the plunger fully forward and see an open conical void, that void is your dead space.
Configuration A — 1 mL luer-lock plus detachable needle, dead space 84 µL: each draw removes 100 + 84 = 184 µL. Draws available from 2,000 µL = 2000 / 184 = 10.87, so 10 full draws.
I would not underestimate the dead-space cost when calculating your true cost per dose.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
The distinction that resolves most of these questions is understanding that dead space is a fixed volume — typically 3 to 5 µL in a fixed-needle syringe and 35 to 100 µL in a luer-lock — and its cost scales with how small your draws are.
The luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.
The switch nearly doubles your vial, which is better than most other optimisations combined.
edited 13 Apr 2025 by marta_okonkwo — clarified the distinction between purity and content
Stated carefully, before anything else: understand that dead space is a property of the syringe architecture, not of the needle gauge.
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.
If cost matters, this is the first thing to change, not the last.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.